Search
EHA 2025: CEO Arthur Sands discusses Nurix Therapeutics' BTK degrader data, the development plan ahead, recent #AACR25 data regarding brain penetration, and activity in the autoimmune space
He discusses the P1 data presented at EHA for CLL and WM, which he says showed efficacy across mutations, durability, and clean safety....
Jun 13
ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders
He discusses Nurix's clinical data set that was presented at ASH. Plus, the company's pipeline, including in the autoimmune space, and...
Dec 10, 2024
Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23
Arthur Sands elaborates on two programs Nurix presented updated data for at ASH and dives into the company's pipeline and partnerships.
Dec 11, 2023
.png){kind=logo}
